Analysts’ recommendations and target prices

Of the 24 analysts covering IBM (IBM) on June 1, seven recommended “buy,” one rated it as “overweight,” 14 recommended “hold,” and two recommended “sell,” as shown in the graph below. Their average target price for IBM was $168.69, whereas the stock closed at $141.95 on June 1. IBM has returned -6.6% in the last year, -0.35% in the last month, and -1.7% in the last week. Peers Microsoft (MSFT), Oracle (ORCL), and Accenture (ACN) have returned 2.5%, 1.9%, and 2.3%, respectively, in the last week.

How Analysts View IBM Stock

Moving average convergence divergence and guidance

On June 1, IBM’s MACD (moving average convergence divergence) reading was -1.6, while Microsoft’s, Oracle’s, and Accenture’s were 1.1, 0.06, and 0.65, respectively. A negative MACD reading indicates that a stock is following a downward trading trend, whereas a positive MACD reading indicates it is heading upward.

This fiscal year, IBM expects non-GAAP EPS of ~$13.80. It expects its free cash flow to fall year-over-year to $12 billion from $13 billion.

Latest articles

Last week (ended August 16) was rough for Canopy Growth (WEED)(CGC) stock. It fell about 14% after the company's fiscal 2020 first-quarter earnings report.

Apple shares rose close to 3% in early hour trading on Monday. So, why is Apple stock trading higher? The market sentiment might have turned positive.

In April, Amazon announced its plan to transform its free two-day shipping program to a free one-day shipping program for its Prime customers.

Cannabis companies face regulatory challenges. Recently, CannTrust (CTST) didn't comply with Health Canada’s regulations.

China’s state media agency, Xinhua News Agency, reported on August 18 that police had seized a FedEx parcel containing a handgun.

As of August 17, Curaleaf Holdings (CURA) (CURLF) was trading at 9.00 Canadian dollars—a fall of 13.5% in August.